Physician profile
Feng Zhao
NPI 1285627083
$1,838.22
in general payments reported to CMS, 2019-2025
15 companies · $640 in 2025
The $640 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.20 · 2020: $98.37 · 2021: $147 · 2022: $192 · 2023: $230 · 2024: $433 · 2025: $640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,302.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,302.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $525.59 | 2021-2025 | Cequa |
| Alcon Vision LLC | $278.48 | 2022-2025 | Rocklatan, Constellation, Tryptyr |
| Abbvie INC. | $231.10 | 2022-2025 | Lumigan, Alphagan P |
| Novartis Pharmaceuticals Corporation | $171.53 | 2020-2023 | |
| Allergan, INC. | $141.35 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $120.09 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $84.39 | 2022-2025 | Tyrvaya |
| Coopervision INC. | $80.73 | 2019 | |
| Dompe US, INC. | $52.28 | 2025 | Oxervate |
| Bausch & Lomb Americas INC. | $43.59 | 2022-2023 | Miebo |
| Harrow Eye, LLC | $28.52 | 2024 | Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $23.28 | 2020 | |
| Aerie Pharmaceuticals, INC. | $22.15 | 2021 | |
| Ge Healthcare | $18.15 | 2025 | |
| Amgen INC. | $16.99 | 2025 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Feng Zhao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.